EIC Accelerator

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

Vivalyx operates a patented organ preservation system designed to enhance the success of organ transplantation. Its technology combines static cold storage with machine perfusion, offering a blood-free alternative that aims to increase the vitality and availability of donor organs, thereby improving patient outcomes.

StarTric develops a minimally invasive device for treating tricuspid regurgitation, a common cause of heart failure. Their transcatheter repair implant reduces blood flow to the lungs, preventing symptoms such as atrial fibrillation and improving patient outcomes.

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

Developer of a revolutionary thrombectomy device designed specifically for treating ischemic stroke. The company's innovative technology enables efficient and safe removal of blood clots from large to small vessels, even in distal regions of the brain, improving patient outcomes.

MyoPax develops advanced regenerative therapies using stem cells to address debilitating muscle illnesses.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

NextKidney is a medical device company that specializes in the development of portable and cost-effective solutions for hemodialysis treatment. Its flagship product, Neokidney, empowers patients by enabling them to perform dialysis at home or on the go, thereby restoring their autonomy and freedom. The Neokidney device is compact enough to fit on a nightstand, minimizing its intrusiveness in personal living spaces. Unlike traditional dialysis systems, which require large fluid volumes, Neokidney utilizes a sorbent cartridge to regenerate dialysis fluid, needing only 5 liters of fluid in bags. This innovative approach simplifies the logistics of dialysis, allowing patients to maintain their social and professional lives without the burden of extensive infrastructure or fluid management.

NanoPhoria is a biotechnology company focused on cardiovascular therapies. It develops non-viral, nanoparticle-based drug delivery platforms designed to target the heart directly and improve the delivery of biologics, including peptides and RNAs. The company is pursuing tissue-directed delivery methods and inhalable formulations, with preclinical programs aimed at treating cardiovascular diseases such as heart failure with reduced ejection fraction. Its platform enables selective organ- and cell-level targeting to expand administration routes beyond traditional systemic delivery, supporting research and development to advance cardiovascular health.

StarTric develops a minimally invasive device for treating tricuspid regurgitation, a common cause of heart failure. Their transcatheter repair implant reduces blood flow to the lungs, preventing symptoms such as atrial fibrillation and improving patient outcomes.

MyoPax develops advanced regenerative therapies using stem cells to address debilitating muscle illnesses.

NextKidney is a medical device company that specializes in the development of portable and cost-effective solutions for hemodialysis treatment. Its flagship product, Neokidney, empowers patients by enabling them to perform dialysis at home or on the go, thereby restoring their autonomy and freedom. The Neokidney device is compact enough to fit on a nightstand, minimizing its intrusiveness in personal living spaces. Unlike traditional dialysis systems, which require large fluid volumes, Neokidney utilizes a sorbent cartridge to regenerate dialysis fluid, needing only 5 liters of fluid in bags. This innovative approach simplifies the logistics of dialysis, allowing patients to maintain their social and professional lives without the burden of extensive infrastructure or fluid management.

Developer of a revolutionary thrombectomy device designed specifically for treating ischemic stroke. The company's innovative technology enables efficient and safe removal of blood clots from large to small vessels, even in distal regions of the brain, improving patient outcomes.

Noah Labs develops innovative technology aimed at the early detection of cardiovascular diseases through voice analysis. Utilizing advanced machine learning software, the company has created a digital health platform that allows patients to record their voices using a smartphone. This platform incorporates patient monitoring and digital biomarkers, providing personalized and predictive virtual care in the comfort of their homes. By focusing on voice-based diagnostics, Noah Labs seeks to empower individuals with cardiovascular conditions to lead healthier and longer lives.

Noah Labs develops innovative technology aimed at the early detection of cardiovascular diseases through voice analysis. Utilizing advanced machine learning software, the company has created a digital health platform that allows patients to record their voices using a smartphone. This platform incorporates patient monitoring and digital biomarkers, providing personalized and predictive virtual care in the comfort of their homes. By focusing on voice-based diagnostics, Noah Labs seeks to empower individuals with cardiovascular conditions to lead healthier and longer lives.

Captor Therapeutics is a bio-pharmaceutical firm focused on development of protein degradation drugs for cancer and autoimmune diseases. Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".

Neurescue ApS, headquartered in Copenhagen, Denmark, specializes in developing innovative medical devices aimed at addressing cardiac arrest and hemorrhage. Established in 2014, the company has introduced its flagship product, the safeREBOA device, which is recognized as the first computer-aided aortic occlusion catheter designed to enhance the care of emergency patients. Neurescue's commitment lies in improving resuscitation rates and extending critical treatment time through advanced cardiovascular solutions. The organization is focused on advancing the clinical utility of its devices to ultimately save lives in emergency situations.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

Arctic Therapeutics is a drug discovery and development company that focuses on identifying the genetic underpinnings of major and rare diseases. It employs bioinformatics and artificial intelligence to mitigate risks and reduce costs and development timelines in traditional drug development, while its research and development is guided by a global team of experts in genetics, genomics, immunology, bioinformatics, and drug development.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

BioSourcing is a biotechnology company based in Liège, Belgium, focused on developing a new generation of biotherapeutics, particularly monoclonal antibodies, to address global unmet medical needs. The company employs advanced technologies, including genome editing techniques like CRISPR, to innovate the design of biotherapeutics. This disruptive approach significantly reduces capital requirements and production costs, especially for large-scale manufacturing, while enhancing the quality and efficiency of biopharmaceuticals through improved glycosylation processes. BioSourcing is committed to sustainability, aiming to minimize the carbon footprint associated with biotherapeutic production. The company boasts a team of leading scientists and international experts, supported by strategic partnerships with key players in the pharmaceutical and biotechnology sectors.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

Omini develops a portable, multiplex biosensor platform for blood testing that enables the simultaneous detection of multiple biomarkers. The device is designed for chronic disease monitoring and therapy management, providing personalized biomarker data to adjust treatments and help prevent acute crises, with applications for general practitioners. Incorporated in 2019 and based in Saint-Mandé, France, Omini aims to offer a low-cost, regular monitoring solution that supports routine assessment of complex conditions such as heart failure.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

Vaxdyn is a biotechnology company focused on the development of vaccines and immunotherapies aimed at preventing infectious diseases, particularly those caused by antibiotic-resistant pathogens. Utilizing innovative technology, Vaxdyn's vaccines incorporate antigens, immunomodulators, nanoparticles, and monoclonal antibodies to effectively combat bacterial infections. This approach helps healthcare professionals mitigate the public health impact of infections that are resistant to traditional treatments. The company actively engages with its customers through various communication channels, including phone, email, and online applications, to address inquiries related to their vaccine offerings.

Implicity develops a software-as-a-service remote monitoring platform for patients with connected pacemakers and defibrillators. The platform collects and analyzes data from cardiac electronic implants, using an artificial intelligence module to sort and summarize information and assess the criticality of alerts within the patient’s medical context. This enables cardiology and other healthcare professionals to automate remote monitoring, consolidate patient telemetry on a single platform, and support timely clinical decision-making to deliver high-quality care.

Chipiron develops portable MRI technology that uses quantum sensing to produce three-dimensional anatomical images at ultra-low magnetic fields. The devices are lightweight, portable, and priced at about one-tenth of conventional MRI systems. The technology supports disease detection, diagnosis, and treatment monitoring, with a focus on brain-related conditions, and aims to reduce fatality rates by expanding access to MRI imaging in diverse clinical settings.

Apmonia Therapeutics develops peptide-based therapies targeting the tumor microenvironment to improve cancer patient outcomes. Their focus includes glioblastoma, ovarian, colorectal, and pancreatic cancers.

Raidium is a Medtech company specializing in radiology-augmented technology. It is developing the first radiological foundation model, often referred to as the "GPT-4" of radiology, to simplify precision medicine. Raidium's deep learning algorithms analyze medical imaging data, providing AI-assisted diagnoses to radiologists via an integrated console. This enables earlier detection and management of serious conditions like cancer and cardiovascular diseases.

Implicity develops a software-as-a-service remote monitoring platform for patients with connected pacemakers and defibrillators. The platform collects and analyzes data from cardiac electronic implants, using an artificial intelligence module to sort and summarize information and assess the criticality of alerts within the patient’s medical context. This enables cardiology and other healthcare professionals to automate remote monitoring, consolidate patient telemetry on a single platform, and support timely clinical decision-making to deliver high-quality care.

BestHealth4U specializes in developing advanced adhesive technologies for medical applications. Their innovative solutions aim to prevent skin injuries, enhance healing, and improve overall patient health by transforming how bandages, dressings, and medical devices adhere to the skin.

Multi4 Medical specializes in developing automated endoscopic technologies for cancer diagnosis and treatment. Their patented technique aims to reduce patient discomfort, accelerate recovery, and lower healthcare costs by enabling procedures in outpatient settings.

Cherry Biotech is a biomedical technology company that develops Organ on Chip instruments and microfluidic systems to culture and mimic human organs under physio-pathological conditions for drug discovery and personalized medicine. The company also offers temperature controllers for rapid temperature shifts and next-generation 3D cell culture technologies to recreate the human cell microenvironment, supporting drug development and toxicity assessment.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

Omini develops a portable, multiplex biosensor platform for blood testing that enables the simultaneous detection of multiple biomarkers. The device is designed for chronic disease monitoring and therapy management, providing personalized biomarker data to adjust treatments and help prevent acute crises, with applications for general practitioners. Incorporated in 2019 and based in Saint-Mandé, France, Omini aims to offer a low-cost, regular monitoring solution that supports routine assessment of complex conditions such as heart failure.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses to enhance T-cell therapies for cancer treatment. Established in 2013, the company focuses on utilizing its patented technology to improve tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibiting antibody treatments. TILT Biotherapeutics is advancing products such as TILT-123, TILT-234, and TILT-321, which aim to modify the tumor microenvironment and boost immune responses against cancer. The company's innovative approach holds promise for achieving effective results in treating solid tumors, paralleling the successes seen in hematological tumors.

neuroClues develops AI-driven eye-tracking technology for clinical use that quantifies neurological function during exams. The platform provides an easy-to-use eye-tracking environment enabling clinicians to assess brain health non-invasively and monitor neurological conditions. By applying AI to eye movement data, the company aims to enable earlier detection of neurological disorders such as Parkinson's and Alzheimer's disease, potentially improving patient outcomes and informing treatment decisions. The approach offers a non-invasive diagnostic aid that can complement traditional assessments and support streamlined clinical workflows.

Medicsen is a start-up focused on healthcare innovation, primarily through the development of advanced technology solutions. A notable project is GlycSen, a needle-free drug delivery device aimed at providing a painless treatment option for individuals with insulin-dependent diabetes. This device integrates data from continuous glucose meters and user-inputted information, utilizing a learning algorithm to facilitate real-time monitoring. It features a chatbot interface that allows patients to easily track their condition, enhancing their ability to manage diabetes effectively. Through these innovations, Medicsen aims to improve the quality of life for those living with chronic diseases.

Gedea Biotech develops an antibiotic-free treatment for vaginal fungal infections using its substance GA101. This natural substance lowers pH, provides physical barrier protection, and inhibits biofilm formation. The company's first product is a topical treatment for vaginal fungal infections.

Qlucore is a prominent provider of advanced bioinformatics software designed for research and precision diagnostics in the life sciences. Founded in 2007 by researchers from Lund University in Sweden, the company aims to simplify the analysis of complex data generated in the fields of genetics and proteomics. Its flagship product, Qlucore Omics Explorer, is a user-friendly bioinformatics tool that enables researchers, technicians, and physicians to easily interpret and visualize large datasets. Additionally, Qlucore offers Qlucore Diagnostics, an AI-powered platform for multi-omics companion and precision diagnostics that integrates with various data-generating instruments. With a global presence, Qlucore serves customers in approximately 35 countries, including leading pharmaceutical companies, hospitals, and academic institutions.

Powerful Medical develops AI-driven cardiovascular care solutions. Its flagship product, PMcardio, improves heart attack detection accuracy, reducing mortality rates and enhancing hospital efficiency. With over 60,000 healthcare professionals on board, it has screened 1.1 million patients across leading health systems. The company's platform offers diagnosis reports, data collection, and personalized treatment plans using AI and machine learning algorithms.

BetaGlue Technologies SpA is a Milan-based company that specializes in the development and manufacture of medical devices designed for loco-regional radiation therapy targeting unresectable solid tumors. The company's innovative product features a proprietary beta-emitting biocompatible matrix, which facilitates the controlled administration of radionuclides directly into tumor masses. This technology not only enhances the effectiveness of cancer treatment but also plays a crucial role in preventing complications that can arise following procedures such as lung and liver biopsies. By focusing on localized therapies, BetaGlue Technologies aims to improve patient outcomes and advance the field of cancer treatment.

Novelrad is a privately held medical device company that specializes in innovative micro-sewing technology. The company has developed a suturing device designed for the closure of vascular and heart defects. This device allows for the deployment of various continuous suture patterns and multipoint purse string sutures, facilitating safe dilation at the start of surgical procedures and ensuring reliable closure at their conclusion. Through its advanced technology, Novelrad aims to enhance surgical outcomes and improve patient safety in cardiovascular surgeries.

Womed SAS, founded in 2018, is a medical device company that originated from research at Professor Garric's biopolymer lab at the University of Montpellier, France. The company focuses on addressing unmet medical needs in gynecologic surgery, particularly intrauterine adhesions, which can impact fertility and pregnancy. Womed develops insertable devices designed to act as mechanical barriers against adhesions, protecting the uterine cavity. These devices are engineered to break up, dissolve, and be naturally discharged without requiring intervention from healthcare professionals, thereby helping women reduce or prevent recurrent intrauterine adhesion formation and miscarriage.

KLISBio is a pioneering company in regenerative medicine that utilizes silk as a versatile and biocompatible scaffold material to advance tissue regeneration methods. The company focuses on various clinical applications within the orthopedic and vascular markets, developing innovative silk-based biomaterials that facilitate the regeneration of human tissues. These materials are designed to degrade safely within the body, making them suitable for medical research and treatment of tissue-related diseases. By harnessing the potential of nano-fibers, KLISBio aims to transform the landscape of medical technology and improve patient outcomes.

O11 Biomedical GmbH is a spin-off from RWTH Aachen University's Institute for Applied Medical Engineering, specifically the Department of Biohybrids & Medical Textiles. The company specializes in liquid breathing technology aimed at treating hypercapnia, a condition characterized by elevated carbon dioxide levels in the blood. O11 Biomedical's innovative technology effectively binds carbon dioxide from intestinal fluid, facilitating its excretion through natural processes. By doing so, the company seeks to enhance both the survival and quality of life for patients afflicted with this respiratory condition.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

Founded in 2017, Nectin Therapeutics develops novel monoclonal antibodies targeting the Nectin family of receptors and ligands. These antibodies aim to treat solid and hematological malignancies by modulating immune checkpoint mechanisms.

DoMore Diagnostics is dedicated to transforming cancer diagnostics through the use of artificial intelligence. The company focuses on developing advanced diagnostic technology that enhances the accuracy of cancer assessments. By predicting the progression of cancer in patients and forecasting potential outcomes, DoMore Diagnostics aims to improve patient care significantly. Their innovative approach not only facilitates tailored treatment options for patients but also enhances the overall efficiency of drug development processes.

Delox designs and develops bio-decontamination devices and automatic decontamination robots that use a solid hydrogen peroxide formulation to deliver rapid, safe disinfection and maintain sterile conditions in healthcare, laboratory and industrial environments. Originating as a spin-off from the University of Lisbon's Faculty of Sciences, the company focuses on compact, cost-effective solutions such as the Delox Box, supported by DeloxHP cartridges that store and release concentrated hydrogen peroxide vapor. Its products enable sterilization of medical devices in hospitals, room decontamination in medical facilities, pharma and food industries, as well as decontamination of laboratory equipment and environmental test chambers. Founded in 2018 and based in Cascais, Portugal, Delox targets facilities that require non-toxic, efficient bio-decontamination to preserve biosafety and reduce downtime.

Powerful Medical develops AI-driven cardiovascular care solutions. Its flagship product, PMcardio, improves heart attack detection accuracy, reducing mortality rates and enhancing hospital efficiency. With over 60,000 healthcare professionals on board, it has screened 1.1 million patients across leading health systems. The company's platform offers diagnosis reports, data collection, and personalized treatment plans using AI and machine learning algorithms.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Hephaistos Pharma is a biotechnology company developing an immunotherapy platform aimed at producing advanced oncology treatments. Its platform enhances commercialized antibodies by stimulating the immune system, turning 'cold' tumors into targets for immune response.

X-trodes develops scalable wireless electronic technology and analytics for biopotential signals, enabling advanced electrophysiological monitoring. Its solution combines wearable hardware with automated, high-resolution analysis to support clinical evaluation and treatment across brain, eye, muscle, and heart signals. The technology is designed to track physiological activity during sleep and everyday tasks, providing objective measurements that can inform medical decisions and help improve patients’ quality of life. By integrating sensors and analytics in a cohesive platform, X-trodes aims to make continuous biopotential monitoring practical in routine healthcare settings, offering clinicians and patients insights into neural, ocular, muscular, and cardiovascular health through a single, scalable system.

X-trodes develops scalable wireless electronic technology and analytics for biopotential signals, enabling advanced electrophysiological monitoring. Its solution combines wearable hardware with automated, high-resolution analysis to support clinical evaluation and treatment across brain, eye, muscle, and heart signals. The technology is designed to track physiological activity during sleep and everyday tasks, providing objective measurements that can inform medical decisions and help improve patients’ quality of life. By integrating sensors and analytics in a cohesive platform, X-trodes aims to make continuous biopotential monitoring practical in routine healthcare settings, offering clinicians and patients insights into neural, ocular, muscular, and cardiovascular health through a single, scalable system.

Picterus is developing an app to diagnose jaundice in newborns, aiming to reduce the global infant mortality associated with this condition. The platform uses a patented color calibration card and smartphone camera for accurate image capture, providing healthcare professionals and caregivers with a reliable tool for early detection and timely intervention.

Better Medicine develops an AI-powered radiology platform aimed at streamlining cancer diagnostics. Its platform offers multi-organ analysis, automated lesion detection, integrated reporting tools, and compatibility with existing systems, enabling healthcare providers to enhance diagnostic accuracy and deliver personalized care.

Angiolutions develops innovative therapeutic devices focused on treating vascular diseases, notably minor abdominal aortic aneurysms. Their groundbreaking approach involves a novel vascular graft designed to halt the growth of these aneurysms.

GeneCode AS creates new disease-modifying pharmaceuticals.

Thirona is a software company that develops AI-powered medical imaging analysis tools and provides image analysis services for the healthcare industry. Its automated tools support the analysis of thoracic CT scans, chest X-rays, and retinal images, delivering accurate and repeatable measurements to help hospitals detect and mitigate diseases. The company offers software solutions and certified image analysis services that streamline imaging workflows and improve diagnostic precision.

Celtic Biotech is a biotechnology company focused on developing innovative therapies for the treatment of solid cancers and pain in humans. Co-founded by John Reid, the company utilizes specialized receptor-binding proteins derived from snake venom to create its therapeutic products. These novel candidate therapies aim to enhance patient survival rates, improve quality of life, and reduce the overall costs of cancer treatment. By leveraging unique biological mechanisms, Celtic Biotech addresses significant medical challenges in oncology and pain management.

GeneCode AS creates new disease-modifying pharmaceuticals.

Cephalgo is a company that specializes in mental health solutions, providing psychiatrists with innovative wearable electroencephalography equipment. This technology allows for the automatic and precise monitoring of emotions through brainwaves, facilitating remote patient tracking. Additionally, Cephalgo has developed a mood tracker platform aimed at enhancing mental health by automatically tracking mood and analyzing emotional profiles. This platform empowers users to access self-help resources and treatment planning, contributing to more effective management of mental health conditions. Through its advanced tools, Cephalgo strives to improve the quality of care in the mental health field.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

Hooke Bio Ltd. is a biotechnology company based in Shannon, Ireland, focused on developing microfluidic technologies for drug screening and related applications. Founded in 2014, the company has created a fully integrated high-throughput screening system that utilizes 3D microtissues, such as spheroids and organoids, to generate biological data. This innovative, patent-protected technology aims to reduce reliance on animal models in preclinical studies and accelerate the drug development process. By enabling pharmaceutical companies and clinicians to develop more accurate disease models and optimize treatments based on individual patient samples, Hooke Bio enhances the ability to test and repurpose drugs effectively, ultimately improving patient care and outcomes.

Luminate Medical specializes in developing innovative medical devices aimed at preventing hair loss during chemotherapy. Recognizing the significant impact of hair loss on patients' self-esteem, the company focuses on utilizing advanced medical technology to protect this essential element of personality.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

Hemispherian is a biotechnology firm focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The company specializes in creating personalized cancer therapies and is engaged in the development of a novel class of small-molecule drugs. By concentrating on areas of unmet medical need, Hemispherian aims to provide physicians with access to advanced therapeutic options that could improve patient outcomes in challenging cancer cases.

ResoTher Pharma is a privately held biotechnology company based in Copenhagen, Denmark. The company specializes in developing peptide-based drugs derived from Annexin A1, an endogenous immunomodulator. These drugs are designed as resolution therapies for diseases where neutrophil-driven inflammation is a key pathological factor. ResoTher Pharma's primary focus is on addressing cardiovascular and inflammatory disorders that have significant unmet medical needs. Their patented peptide drugs target a G-protein coupled receptor expressed on leukocytes, aiming to mimic the body's natural response to resolving inflammation and promoting tissue repair.

Strolll is a digital health company focused on improving mobility for people with neurological disorders. It develops a B2B digital therapeutics platform that delivers clinically validated rehabilitation software on off-the-shelf augmented reality glasses. The platform supports both in-clinic (synchronous) and at-home (asynchronous) therapy, enabling rehabilitation clinics to scale services, improve access, and reduce the cost of neurorehabilitation. By personalizing therapy, the solution aims to increase patient adherence and outcomes while streamlining administrative processes and delivering meaningful data to clinics.

Founded in 2017, SolasCure is a biotechnology company based in Wales, UK. It specializes in developing innovative hydrogel treatments for patients with chronic wounds. Its flagship product, Aurase, facilitates wound debridement, removing dead or infected tissue to enhance healing.

MaxiVAX is a Swiss clinical-stage biotechnology company developing personalized cancer immunotherapies. Its lead product, MVX-ONCO-1, is an advanced therapeutic product for various tumors, currently in phase I trials.